Health and Economic Impact of Different Long-Term Oxygen Therapeutic Strategies in Patients with Chronic Respiratory Failure: A French Nationwide Health Claims Database (SNDS) Study

Overview

Journal Pulm Ther

Publisher Springer

Date 2024 Jun 1

PMID 38822956

Authors

Stanislav Glezer

Gregoire Mercier

Jean-Marc Coursier

Nicoleta Petrica

Maria Pini

Abhijith Pg

Affiliations

Soon will be listed here.

Abstract

Introduction: Long-term oxygen therapy (LTOT) is reported to improve survival in patients with chronic respiratory failure. We aimed to describe effectiveness, burden, and cost of illness of patients treated with portable oxygen concentrators (POC) compared to other LTOT options.

Methods: This retrospective comparative analysis included adult patients with chronic respiratory insufficiency and failure (CRF) upon a first delivery of LTOT between 2014 and 2019 and followed until December 2020, based on the French national healthcare database SNDS. Patients using POC, alone or in combination, were compared with patients using stationary concentrators alone (aSC), or compressed tanks (CTC) or liquid oxygen (LO2), matched on the basis of age, gender, comorbidities, and stationary concentrator use.

Results: Among 244,719 LTOT patients (mean age 75 ± 12, 48% women) included, 38% used aSC, 46% mobile oxygen in the form of LO2 (29%) and POC (18%), whereas 9% used CTC. The risk of death over the 72-month follow-up was estimated to be 13%, 15%, and 12% lower for patients in the POC group compared to aSC, CTC, and LO2, respectively. In the POC group yearly mean total costs per patient were 5% higher and 4% lower compared to aSC and CTC groups, respectively, and comparable in the LO2 group. The incremental cost-effectiveness ratio (ICER) of POC was €8895, €6288, and €13,152 per year of life gained compared to aSC, CTC, and LO2, respectively.

Conclusion: Within the POC group, we detected an association between higher mobility (POCs autonomy higher than 5 h), improved survival, lower costs, and ICER - €6 238, compared to lower mobility POCs users.

Citing Articles

The Value of Tracheal Visualization in Tracheostomized Patients in Skilled and Long-Term Care Homes.

Ferrer G, Alas-Pineda C, Manara V, Tesch M, Gaitan-Zambrano K, Pavon-Varela D Cureus. 2025; 17(1):e76748.

PMID: 39758865 PMC: 11698548. DOI: 10.7759/cureus.76748.

References

Tuppin P, Rudant J, Constantinou P, Gastaldi-Menager C, Rachas A, de Roquefeuil L . Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017; 65 Suppl 4:S149-S167. DOI: 10.1016/j.respe.2017.05.004. View

Wouters E . Economic analysis of the Confronting COPD survey: an overview of results. Respir Med. 2003; 97 Suppl C:S3-14. DOI: 10.1016/s0954-6111(03)80020-3. View

Dakkak J, Tang W, Smith J, Balasubramanian A, Mattson M, Ainechi A . Burden and Unmet Needs with Portable Oxygen in Patients on Long-Term Oxygen Therapy. Ann Am Thorac Soc. 2021; 18(9):1498-1505. DOI: 10.1513/AnnalsATS.202005-487OC. View

Iheanacho I, Zhang S, King D, Rizzo M, Ismaila A . Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020; 15:439-460. PMC: 7049777. DOI: 10.2147/COPD.S234942. View

Kim S, Shin Y, Shin M, Hong C, Huh S, Yoo W . Effects of walking with a portable oxygen concentrator on muscle oxygenation while performing normal or pursed-lip breathing in patients with interstitial lung disease: a randomized crossover trial. Ther Adv Respir Dis. 2023; 17:17534666231186732. PMC: 10357056. DOI: 10.1177/17534666231186732. View

Sami R, Savari M, Mansourian M, Ghazavi R, Meamar R . Effect of Long-Term Oxygen Therapy on Reducing Rehospitalization of Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Pulm Ther. 2023; 9(2):255-270. PMC: 10203089. DOI: 10.1007/s41030-023-00221-3. View

Burgel P, Laurendeau C, Raherison C, Fuhrman C, Roche N . An attempt at modeling COPD epidemiological trends in France. Respir Res. 2018; 19(1):130. PMC: 6022451. DOI: 10.1186/s12931-018-0827-7. View

Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 4(10):e297. PMC: 2020496. DOI: 10.1371/journal.pmed.0040297. View

Foo J, Landis S, Maskell J, Oh Y, van der Molen T, Han M . Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries. PLoS One. 2016; 11(4):e0152618. PMC: 4836731. DOI: 10.1371/journal.pone.0152618. View

10.

Olaya B, Moneta M, Domenech-Abella J, Miret M, Bayes I, Ayuso-Mateos J . Mobility Difficulties, Physical Activity, and All-cause Mortality Risk in a Nationally representative Sample of Older Adults. J Gerontol A Biol Sci Med Sci. 2017; 73(9):1272-1279. DOI: 10.1093/gerona/glx121. View

11.

Wilson K, Gould M, Krishnan J, Boyd C, Brozek J, Cooke C . An Official American Thoracic Society Workshop Report. A Framework for Addressing Multimorbidity in Clinical Practice Guidelines for Pulmonary Disease, Critical Illness, and Sleep Disorders. Ann Am Thorac Soc. 2016; 13(3):S12-21. PMC: 5884100. DOI: 10.1513/AnnalsATS.201601-007ST. View

12.

Gilbert T, Cordier Q, Polazzi S, Bonnefoy M, Keeble E, Street A . External validation of the Hospital Frailty Risk Score in France. Age Ageing. 2021; 51(1). PMC: 8753041. DOI: 10.1093/ageing/afab126. View

13.

Moller S, Ivarsson B, Nordstrom L, Johansson A . LTOT Patients' Experience of a Portable Oxygen Unit and Health-Related Quality of Life-A Cross-Sectional Study. Healthcare (Basel). 2020; 8(2). PMC: 7349300. DOI: 10.3390/healthcare8020182. View

14.

Li Y, Li L . Propensity score analysis methods with balancing constraints: A Monte Carlo study. Stat Methods Med Res. 2021; 30(4):1119-1142. PMC: 9161720. DOI: 10.1177/0962280220983512. View

15.

Srivastava K, Thakur D, Sharma S, Punekar Y . Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoeconomics. 2015; 33(5):467-88. DOI: 10.1007/s40273-015-0252-4. View

16.

Khor Y, McDonald C, Hazard A, Symons K, Westall G, Glaspole I . Portable oxygen concentrators versus oxygen cylinder during walking in interstitial lung disease: A randomized crossover trial. Respirology. 2017; 22(8):1598-1603. DOI: 10.1111/resp.13083. View

17.

Divo M, Marin J, Casanova C, Cabrera Lopez C, Pinto-Plata V, Marin-Oto M . Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease. Respir Res. 2022; 23(1):267. PMC: 9516817. DOI: 10.1186/s12931-022-02191-7. View

18.

Dal Negro R, Bonadiman L, Bricolo F, Tognella S, Turco P . Cognitive dysfunction in severe chronic obstructive pulmonary disease (COPD) with or without Long-Term Oxygen Therapy (LTOT). Multidiscip Respir Med. 2015; 10(1):17. PMC: 4415443. DOI: 10.1186/s40248-015-0013-4. View

19.

Argano C, Scichilone N, Natoli G, Nobili A, Corazza G, Mannucci P . Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry. Intern Emerg Med. 2020; 16(2):389-400. PMC: 7384278. DOI: 10.1007/s11739-020-02412-1. View

20.

Melani A, Sestini P, Rottoli P . Home oxygen therapy: re-thinking the role of devices. Expert Rev Clin Pharmacol. 2017; 11(3):279-289. DOI: 10.1080/17512433.2018.1421457. View